Shares of Edap TMS EDAP were flat after the company reported Q3 results.
Earnings per share decreased 233.33% over the past year to ($0.04), which missed the estimate of ($0.02).
Revenue of $11,176,000 decreased by 1.36% from the same period last year, which beat the estimate of $9,290,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 18, 2020
Time: 08:30 AM
ET Webcast URL: http://public.viavid.com/player/index.php?id=142115
Company's 52-week high was at $5.39
52-week low: $1.46
Price action over last quarter: Up 19.03%
Edap TMS SAis a holding company operating in two divisions namely, High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU division develops, manufactures and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets two HIFU devices: the Ablatherm, treatment of organ-confined prostate cancer; and the Focal One, for the focal therapy of localized prostate cancer destroying targeted cancer cells only. The UDS division develops, markets, manufactures and services medical devices for the invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The business of the presence of the firm are sen Asia, France, United States and other regions.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.